George Quentin Daley, M.D., Ph.D.
This page shows the publications co-authored by George Daley and Valentina Nardi.
ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood. 2009 Apr 16; 113(16):3813-20.
Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82.
Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004 Jan; 11(1):35-43.
Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009 Jul 09; 460(7252):259-63.
Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9.
Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9244-9.
A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003; 5:204-210.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.